126 related articles for article (PubMed ID: 8106293)
1. Chemical modification of natural human tumor necrosis factor-alpha with polyethylene glycol increases its anti-tumor potency.
Tsutsumi Y; Kihira T; Yamamoto S; Kubo K; Nakagawa S; Miyake M; Horisawa Y; Kanamori T; Ikegami H; Mayumi T
Jpn J Cancer Res; 1994 Jan; 85(1):9-12. PubMed ID: 8106293
[TBL] [Abstract][Full Text] [Related]
2. Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency.
Tsutsumi Y; Kihira T; Tsunoda S; Kanamori T; Nakagawa S; Mayumi T
Br J Cancer; 1995 May; 71(5):963-8. PubMed ID: 7734321
[TBL] [Abstract][Full Text] [Related]
3. Molecular design of hybrid tumor necrosis factor-alpha III: polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation.
Tsutsumi Y; Kihira T; Tsunoda S; Kamada H; Nakagawa S; Kaneda Y; Kanamori T; Mayumi T
J Pharmacol Exp Ther; 1996 Sep; 278(3):1006-11. PubMed ID: 8819479
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of tumor necrosis factor-alpha conjugated with polyvinylpyrrolidone on solid tumors in mice.
Kamada H; Tsutsumi Y; Yamamoto Y; Kihira T; Kaneda Y; Mu Y; Kodaira H; Tsunoda SI; Nakagawa S; Mayumi T
Cancer Res; 2000 Nov; 60(22):6416-20. PubMed ID: 11103807
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumor potency of polyethylene glycolylated tumor necrosis factor-alpha: a novel polymer-conjugation technique with a reversible amino-protective reagent.
Tsunoda S; Ishikawa T; Yamamoto Y; Kamada H; Koizumi K; Matsui J; Tsutsumi Y; Hirano T; Mayumi T
J Pharmacol Exp Ther; 1999 Jul; 290(1):368-72. PubMed ID: 10381801
[TBL] [Abstract][Full Text] [Related]
6. Molecular design of hybrid tumour necrosis factor-alpha. II: The molecular size of polyethylene glycol-modified tumour necrosis factor-alpha affects its anti-tumour potency.
Tsutsumi Y; Tsunoda S; Kamada H; Kihira T; Nakagawa S; Kaneda Y; Kanamori T; Mayumi T
Br J Cancer; 1996 Oct; 74(7):1090-5. PubMed ID: 8855980
[TBL] [Abstract][Full Text] [Related]
7. Intravenous administration of polyethylene glycol-modified tumor necrosis factor-alpha completely regressed solid tumor in Meth-A murine sarcoma model.
Tsutsumi Y; Kihira T; Tsunoda S; Kubo K; Miyake M; Kanamori T; Nakagawa S; Mayumi T
Jpn J Cancer Res; 1994 Dec; 85(12):1185-8. PubMed ID: 7852179
[TBL] [Abstract][Full Text] [Related]
8. Optimal site-specific PEGylation of mutant TNF-alpha improves its antitumor potency.
Yoshioka Y; Tsutsumi Y; Ikemizu S; Yamamoto Y; Shibata H; Nishibata T; Mukai Y; Okamoto T; Taniai M; Kawamura M; Abe Y; Nakagawa S; Nagata S; Yamagata Y; Mayumi T
Biochem Biophys Res Commun; 2004 Mar; 315(4):808-14. PubMed ID: 14985084
[TBL] [Abstract][Full Text] [Related]
9. In vivo anti-tumor efficacy of polyethylene glycol-modified tumor necrosis factor-alpha against tumor necrosis factor-resistant tumors.
Tsutsumi Y; Tsunoda S; Kaneda Y; Kamada H; Kihira T; Nakagawa S; Yamamoto Y; Horisawa Y; Mayumi T
Jpn J Cancer Res; 1996 Oct; 87(10):1078-85. PubMed ID: 8957067
[TBL] [Abstract][Full Text] [Related]
10. Molecular design of conjugated tumor necrosis factor-alpha: synthesis and characteristics of polyvinyl pyrrolidone modified tumor necrosis factor-alpha.
Kamada H; Tsutsumi Y; Tsunoda S; Kihira T; Kaneda Y; Yamamoto Y; Nakagawa S; Horisawa Y; Mayumi T
Biochem Biophys Res Commun; 1999 Apr; 257(2):448-53. PubMed ID: 10198233
[TBL] [Abstract][Full Text] [Related]
11. Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window.
Shibata H; Yoshioka Y; Ikemizu S; Kobayashi K; Yamamoto Y; Mukai Y; Okamoto T; Taniai M; Kawamura M; Abe Y; Nakagawa S; Hayakawa T; Nagata S; Yamagata Y; Mayumi T; Kamada H; Tsutsumi Y
Clin Cancer Res; 2004 Dec; 10(24):8293-300. PubMed ID: 15623605
[TBL] [Abstract][Full Text] [Related]
12. Preparation and evaluation of a new releasable PEGylated tumor necrosis factor-α (TNF-α) conjugate for therapeutic application.
Dai C; Fu Y; Chen S; Li B; Yao B; Liu W; Zhu L; Chen N; Chen J; Zhang Q
Sci China Life Sci; 2013 Jan; 56(1):51-8. PubMed ID: 23314867
[TBL] [Abstract][Full Text] [Related]
13. PEGylated recombinant human tumor necrosis factor alpha: pharmacokinetics and anti-tumor effects.
Li YP; Pei YY; Zhou ZH; Zhang XY; Gu ZH; Ding J; Gao XJ; Zhu JH
Biol Pharm Bull; 2001 Jun; 24(6):666-70. PubMed ID: 11411556
[TBL] [Abstract][Full Text] [Related]
14. Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration.
Gao JQ; Eto Y; Yoshioka Y; Sekiguchi F; Kurachi S; Morishige T; Yao X; Watanabe H; Asavatanabodee R; Sakurai F; Mizuguchi H; Okada Y; Mukai Y; Tsutsumi Y; Mayumi T; Okada N; Nakagawa S
J Control Release; 2007 Sep; 122(1):102-10. PubMed ID: 17628160
[TBL] [Abstract][Full Text] [Related]
15. PEGylated recombinant human tumor necrosis factor alpha: preparation and anti-tumor potency.
Li YP; Pei YY; Ding J; Shen ZM; Zhang XY; Gu ZH; Zhou JJ
Acta Pharmacol Sin; 2001 Jun; 22(6):549-55. PubMed ID: 11747763
[TBL] [Abstract][Full Text] [Related]
16. Preclinical investigation of PEGylated tumor necrosis factor alpha in dogs with spontaneous tumors: phase I evaluation.
Thamm DH; Kurzman ID; Clark MA; Ehrhart EJ; Kraft SL; Gustafson DL; Vail DM
Clin Cancer Res; 2010 Mar; 16(5):1498-508. PubMed ID: 20160058
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic, biodistribution, and biophysical profiles of TNF nanobodies conjugated to linear or branched poly(ethylene glycol).
Vugmeyster Y; Entrican CA; Joyce AP; Lawrence-Henderson RF; Leary BA; Mahoney CS; Patel HK; Raso SW; Olland SH; Hegen M; Xu X
Bioconjug Chem; 2012 Jul; 23(7):1452-62. PubMed ID: 22731748
[TBL] [Abstract][Full Text] [Related]
18. Linkage with cathepsin B-sensitive dipeptide promotes the in vitro and in vivo anticancer activity of PEGylated tumor necrosis factor-alpha (TNF-α) against murine fibrosarcoma.
Dai C; Fu Y; Li B; Wang Y; Zhang X; Wang J; Zhang Q
Sci China Life Sci; 2011 Feb; 54(2):128-38. PubMed ID: 21318482
[TBL] [Abstract][Full Text] [Related]
19. Selective enhancer of tumor vascular permeability for optimization of cancer chemotherapy.
Yoshioka Y; Tsutsumi Y; Kamada H; Kihira T; Tsunoda S; Yamamoto Y; Okamoto T; Shibata H; Mukai Y; Taniai M; Shimizu T; Kawamura M; Abe Y; Nakagawa S; Mayumi T
Biol Pharm Bull; 2004 Mar; 27(3):437-9. PubMed ID: 14993819
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of tumor necrosis factor alpha conjugated with divinyl ether and maleic anhydride copolymer on solid tumors in mice.
Kaneda Y; Yamamoto Y; Kamada H; Tsunoda S; Tsutsumi Y; Hirano T; Mayumi T
Cancer Res; 1998 Jan; 58(2):290-5. PubMed ID: 9443407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
